Chemotherapy and targeted agents for thymic malignancies

References

• Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J. Thorac. Oncol.4(1), 119–126 (2009).
   Google Scholar
• WHO histological classification of tumours of the thymus. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France, 146 (2004).
   Google Scholar
• Girard N. Thymic tumors: relevant molecular data in the clinic. J. Thorac. Oncol.5(10S4), S291–S295 (2010).
   Google Scholar
• Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR Jr. Thymic carcinoma: state of the art review. Int. J. Radiat. Oncol. Biol. Phys.59(3), 654–664 (2004).
   PubMedGoogle Scholar
• Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer48(11), 2485–2492 (1981).
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka–Koga stage classification for thymic malignancies: clarification and definition of terms. J. Thorac. Oncol.6(7 S3), S1710–S1716 (2011).
   Google Scholar
• Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann. Thorac. Surg.76(3), 878–884 (2003).
   PubMed Web of Science ®Google Scholar
• Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J. Thorac. Oncol.6(7S3), S1749–S1755 (2011).
   Google Scholar
• Girard N, Shen R, Guo T et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin. Cancer Res.15(122), 6790–6799 (2009).
   Google Scholar
• Girard N, Teruya-Feldstein J, Payabyab EC et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J. Thorac. Oncol.5(9), 1439–1446 (2010).
   Google Scholar
• Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J. Thorac. Oncol.6(7S3), S1698–S1704 (2011).
   Google Scholar
• Macchiarini P, Chella A, Ducci F et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer68(4), 706–713 (1991).
   PubMed Web of Science ®Google Scholar
• Berruti A, Borasio P, Roncari A, Gorzegno G, Mossetti C, Dogliotti L. Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann. Oncol.4(5), 429–431 (1993).
   PubMedGoogle Scholar
• Rea F, Sartori F, Loy M et al. Chemotherapy and operation for invasive thymoma. J. Thorac. Cardiovasc. Surg.106(3), 543–549 (1993).
   PubMedGoogle Scholar
• Berruti A, Borasio P, Gerbino A et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br. J. Cancer81(5), 841–845 (1999).
   Google Scholar
• Venuta F, Rendina EA, Longo F et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann. Thorac. Surg.76(6), 1866–1872 (2003).
   PubMed Web of Science ®Google Scholar
• Bretti S, Berruti A, Loddo C et al. Multimodal management of stages III–IVa malignant thymoma. Lung Cancer44(1), 69–77 (2004).
   Google Scholar
• Kim ES, Putnam JB, Komaki R et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer44(3), 369–379 (2004).
   PubMed Web of Science ®Google Scholar
• Lucchi M, Ambrogi MC, Duranti L et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann. Thorac. Surg.79(6), 1840–1844 (2005).
   Google Scholar
• Jacot W, Quantin X, Valette S et al. Multimodality treatment program in invasive thymic epithelial tumor. Am. J. Clin. Oncol.28(1), 5–7 (2005).
   Google Scholar
• Yokoi K, Matsuguma H, Nakahara R et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J. Thorac. Oncol.2(1), 73–78 (2007).
   PubMed Web of Science ®Google Scholar
• Kunitoh H, Tamura T, Shibata T et al. A Phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br. J. Cancer103(1), 6–11 (2010).
   Google Scholar
• Loehrer PJ Sr, Chen M, Kim K et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J. Clin. Oncol.15(9), 3093–3099 (1997).
   PubMed Web of Science ®Google Scholar
• Wright CD, Choi NC, Wain JC, Mathisen DJ, Lynch TJ, Fidias P. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVa thymic tumors. Ann. Thorac. Surg.85(2), 385–389 (2008).
   Google Scholar
• Fuller CD, Housman DM, Thomas CR. Radiotherapy for thymoma and thymic carcinoma. Hematol. Oncol. Clin. North. Am.22(3), 489–507 (2008).
   Google Scholar
• Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am. J. Clin. Oncol.27(1), 68–72 (2004).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma: a decade experience at a single institution. Am. J. Clin. Oncol.29(4), 336–344 (2006).
   PubMed Web of Science ®Google Scholar
• Huang J, Rizk NP, Travis WD et al. Feasibility of multimodality therapy including extended resections in stage IVa thymoma. J. Thorac. Cardiovasc. Surg.134(6), 1477–1483 (2007).
   Google Scholar
• Cowen D, Richaud P, Mornex F et al. Thymoma: results of a multicentric retrospective series of 149 nonmetastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother. Oncol.34(1), 9–16 (1995).
   PubMed Web of Science ®Google Scholar
• Kitami A, Suzuki T, Kamio Y, Suzuki S. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J. Clin. Oncol.31(12), 601–604 (2001).
   Google Scholar
• Shin DM, Walsh GL, Komaki R et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann. Intern. Med.129(2), 100–104 (1998).
   PubMedGoogle Scholar
• Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 Phase II trial of cisplatin in metastatic or recurrent thymoma. Am. J. Clin. Oncol.16(4), 342–345 (1993).
   PubMedGoogle Scholar
• Highley MS, Underhill CR, Parnis FX et al. Treatment of invasive thymoma with single-agent ifosfamide. J. Clin. Oncol.17(9), 2737–2744 (1999).
   Google Scholar
• Loehrer PJ, Yiannoutsos CT, Dropcho S et al. A Phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol.24(18S), 7079 (2006).
   Google Scholar
• Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy of invasive thymoma. J. Clin. Oncol.8(8), 1419–1423 (1990).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Kim K, Aisner SC et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J. Clin. Oncol.12(6), 1164–1168 (1994).
   PubMedGoogle Scholar
• Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol.14(3), 814–820 (1996).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Jiroutek M, Aisner S et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer91(11), 2010–2015 (2001).
   PubMed Web of Science ®Google Scholar
• Lemma GL, Lee JW, Aisner SC et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J. Clin. Oncol.29(15), 2060–2065 (2011).
   PubMedGoogle Scholar
• Palmieri G, Merola G, Federico P et al. Preliminary results of Phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann. Oncol.21(6), 1168–1172 (2010).
   Google Scholar
• Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer74(3), 492–496 (2011).
   Google Scholar
• Grassin F, Paleiron N, André M et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J. Thorac. Oncol.5(6), 893–897 (2010).
   Google Scholar
• Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J. Thorac. Oncol.6(7 Suppl. 3), S1691–S1697 (2011).
   Google Scholar
• Lara PN Jr, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest110(4), 1115–1117 (1996).
   Google Scholar
• Mygland A, Vincent A, Newsom-Davis J et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch. Neurol.57(4), 527–531 (2000).
   PubMedGoogle Scholar
• Loehrer PJ Sr, Wang W, Johnson DH. Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J. Clin. Oncol.22(2), 293–299 (2004).
   PubMed Web of Science ®Google Scholar
• Palmieri G, Montella L, Martignetti A et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer94(5), 1414–1420 (2002).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature455(7216), 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Shedden K, Taylor JM, Enkemann SA et al. Gene expression-based survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat. Med.14(8), 822–827 (2008).
   PubMed Web of Science ®Google Scholar
• Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature450(7171), 893–898 (2007).
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol.12(2), 175–180 (2011).
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heel of cancer. Science297(5578), 63–64 (2002).
   PubMed Web of Science ®Google Scholar
• Breinig M, Mayer P, Harjung A et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin. Cancer Res.17(8), 2237–2249 (2011).
   Google Scholar
• Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol. Oncol. Clin. North Am.22(3), 443–455 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki E, Sasaki H, Kawano O et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn. J. Clin. Oncol.36(6), 351–356 (2006).
   PubMed Web of Science ®Google Scholar
• Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer103(3), 630–636 (2005).
   PubMed Web of Science ®Google Scholar
• Yoh K, Nishiwaki Y, Ishii G et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer62(3), 316–320 (2008).
   Google Scholar
• Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer52(2), 261–262 (2006).
   Google Scholar
• Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J. Clin. Oncol.23(Suppl. 16), 7068 (2005).
   Google Scholar
• Suzuki M, Chen H, Shigematsu H et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol. Rep.14(6), 1621–1624 (2005).
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yano M, Fujii Y. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. J. Thorac. Oncol.5(10), 1715–1716 (2010).
   Google Scholar
• Bedano PM, Perkins S, Burns M et al. A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol.15(Suppl.), 19087 (2008).
   Google Scholar
• Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol.8(5), 449–450 (2007).
   Google Scholar
• Palmieri G, Marino M, Salvatore M et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci.12, 757–761 (2007).
   PubMedGoogle Scholar
• Christodoulou C, Murray S, Dahabreh J et al. Response of malignant thymoma to erlotinib. Ann. Oncol.19(7), 1361–1362 (2008).
   Google Scholar
• Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J. Cancer. Res. Clin. Oncol.130(4), 222–224 (2004).
   PubMedGoogle Scholar
• Ströbel P, Bargou R, Wolff A et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br. J. Cancer103(2), 196–200 (2010).
   Google Scholar
• Ströbel P, Hartmann M, Jakob A et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N. Engl. J. Med.350(25), 2625–2626 (2004).
   PubMedGoogle Scholar
• Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med. Oncol.26(2), 157–160 (2009).
   PubMed Web of Science ®Google Scholar
• Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long lasting response to the multikinase inhibitor bay 43–9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J. Thorac. Oncol.4(6), 773–775 (2009).
   PubMed Web of Science ®Google Scholar
• Dişel U, Oztuzcu S, Beşen AA et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer71(1), 109–112 (2011).
   Google Scholar
• Buti S, Donini M, Sergio P et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol.29(33), e803–e805 (2011).
   Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol.26(33), 5352–5359 (2008).
   PubMed Web of Science ®Google Scholar
• Palmieri G, Marino M, Buonerba C et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother. Pharmacol.69(2), 309–315 (2012).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J. Thorac. Oncol.4(10), 1270–1273 (2009).
   PubMed Web of Science ®Google Scholar
• Salter JT, Lewis D, Yiannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 8116).
   Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer8(12), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Gong Y, Yao E, Shen R et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One4(10), e7273 (2009).
   PubMed Web of Science ®Google Scholar
• Zucali PA, Petrini I, Lorenzi E et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer116(20), 4686–4695 (2010).
   PubMed Web of Science ®Google Scholar
• Haluska P, Shaw H, Batzel GN et al. Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer. Res.13(19), 5834–5840 (2007).
   PubMed Web of Science ®Google Scholar
• Cimpean AM, Raica M, Encica S et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann. Anat.190(3), 238–245 (2008).
   PubMed Web of Science ®Google Scholar
• Marino M, Piantelli M. Immunohistochemistry of thymic epithelial tumors as a tool in translational research. J. Thorac. Surg. Clin.21(1), 33–46 (2011).
   Google Scholar
• Tomita M, Matsuzaki Y, Edagawa M et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J. Thorac. Cardiovasc. Surg.124(3), 493–498 (2002).
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yukiue H, Kobayashi Y et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg. Today31(11), 1038–1040 (2001).
   PubMedGoogle Scholar
• Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A Phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3599).
   Google Scholar
• Chuah C, Lim TH, Lim AS et al. Dasatinib induces a response in malignant thymoma. J. Clin. Oncol.24(34), e56–e58 (2006).
   PubMed Web of Science ®Google Scholar
• Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbutt NC. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta. Oncol.48(4), 619–621 (2009).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Rajan A, Berman A et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol.29(15), 2052–2059 (2011).
   PubMed Web of Science ®Google Scholar
• Hirabayashi H, Fujii Y, Sakaguchi M et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int. J. Cancer73(5), 639–644 (1997).
   PubMed Web of Science ®Google Scholar
• Tagawa T, Ohta M, Kuwata T, Awaya H, Ishida T. S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma. J. Thorac. Oncol.5(4), 572–573 (2010).
   Google Scholar
• Okuma Y, Shimokawa T, Takagi Y et al. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer70(3), 357–363 (2010).
   Google Scholar
• Kirkove C, Berghmans J, Noel H, van de Merckt J. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin. Oncol. (R. Coll. Radiol.)4(1), 64–66 (1992).
   Google Scholar
• Craven C, Reddy PK, Ringel SP, Rutherford RB. Effect of corticosteroids on the thymus in myasthenia gravis. Muscle Nerve4(5), 425–428 (1981).
   Google Scholar
• Yarom N, Zissin R, Apter S, Hertz M, Rahimi-Levene N, Gayer G. Rebound thymic enlargement on CT in adults. Int. J. Clin. Pract.61(4), 562–568 (2007).
   Google Scholar
• Aisner SC, Dahlberg S, Hameed MR et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J. Thoracic. Oncol.5(6), 885–892 (2010).
   Google Scholar
• Mineo TC, Ambrogi V, Baldi A, Pompeo E, Mineo D. Recurrent intrathoracic thymomas: potential prognostic importance of cell-cycle protein expression. J. Thorac. Cardiovasc. Surg.138(1), 40–45 (2009).
   Google Scholar
• Petrini I, Wang Y, Pineda M, Davis S, Giaccone G. O40.01 complete genome sequencing of a human B3 thymoma. J. Thorac. Oncol.6(6), S452 (2011).
   Google Scholar
• Kaira K, Serizawa M, Koh Y et al. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer74(3), 419–25 (2011).
   Google Scholar